The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Recap by typeshit. Full story at ad-hoc-news.de.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
He says this average comes from his own clinical experience, adding that some strong responders drop more than 10 kg. A personal observation, not trial data.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
A short primer on peptides as amino acid chains, noting that many wellness versions sold online lack FDA approval.
Loading…